Psychedelic Research in
Antigua and Barbuda
Antigua and Barbuda has a restrictive controlled-drug framework for psychedelics and related substances. The country's Misuse of Drugs legislation controls production, possession, supply, import and export, while allowing limited authorisation for otherwise unlawful activities under statutory provisions.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Antigua and Barbuda.
- 1
The legal framework is control-first: psychedelics are not presented as routinely available medicines, and any non-standard use would need explicit authorisation. ([sherloc.unodc.org](https://sherloc.unodc.org/cld/document/atg/1973/the_misuse_of_drugs_act_1973.html?utm_source=openai))
- 2
Public-facing health sources point to ordinary pharmaceutical and controlled-drug governance rather than a dedicated psychedelic medicine programme. ([health.gov.ag](https://health.gov.ag/pharmaceutical-division/?utm_source=openai))
- 3
A statutory medicinal cannabis authority exists, which shows the country can create narrow regulated-access regimes, but that does not imply similar access for classic psychedelics. ([mca.gov.ag](https://mca.gov.ag/?utm_source=openai))
- 4
I found no credible evidence in the reviewed sources of active local psychedelic clinical trials, which is consistent with Blossom's zero linked-trial snapshot. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41699126/?utm_source=openai))
- 5
Recent policy signals are more visible in cannabis and pharmaceutical regulation than in psychedelics-specific reform. ([mca.gov.ag](https://mca.gov.ag/?utm_source=openai))
Research Snapshot
Blossom currently keeps Antigua and Barbuda as a country index, but no psychedelic clinical trials, stakeholders or events are linked to this country in the database yet.
Missing linked records are database coverage signals, not proof that no local policy discussion, care or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 0
- Events
- 0
None marked active
No linked trials
No linked stakeholders
No linked events
Top Compounds
No headline compound signal is available from linked country trials yet.
Top Study Topics
No study-topic signal is available from linked country trials yet.
Medical Access Snapshot
Antigua and Barbuda regulates psychoactive substances under its Misuse of Drugs legislation (principal Misuse of Drugs Act and subsequent amendments). Conventional medical use of ketamine for anesthesia is recognized in practice (and ketamine is on the WHO Model List of Essential Medicines), but most classical psychedelics (psilocybin, MDMA, DMT variants, mescaline, ibogaine, 2C-series, ayahuasca) are controlled under national scheduling and have no routine reimbursed medical pathway outside authorised research. National law provides for exemptions for...
Regulatory Status
Antigua and Barbuda appears to keep classical psychedelics under controlled-drug law, with medical or scientific use possible only where expressly authorised under the Misuse of Drugs framework. A 2018 amendment is listed by WHO MiNDbank, and UNODC materials show the Act's restrictions on import/export, possession, supply and cultivation, plus an authorisation mechanism; however, the precise operational pathway for research or special access is not fully clear from the public materials reviewed, so this should be treated cautiously. ([sherloc.unodc.org](https://sherloc.unodc.org/cld/document/atg/1973/the_misuse_of_drugs_act_1973.html?utm_source=openai))
Country Details
- Region
- North America
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Antigua and Barbuda regulates psychoactive substances under its Misuse of Drugs legislation (principal Misuse of Drugs Act and subsequent amendments). Conventional medical use of ketamine for anesthesia is recognized in practice (and ketamine is on the WHO Model List of Essential Medicines), but...
Open access guide →